New agent developed for prostate cancer diagnosis, treatment

22 junio 2015

An agent called PSMA-617 is capable of attaching specifically to prostate cancer cells. This agent can be labeled with various radioactive substances. When chemically bound to a weakly radioactive diagnostic radionuclide, it can detect prostate tumors and their metastases in PET scans. If labeled with a strongly radioactive therapeutic radionuclide, PSMA-617 can specifically destroy cancer cells. A first clinical application of this radiopharmaceutica has now delivered promising results.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/PVK2gs4r64k/150622124622.htm

Volver